Evotec is double dipping into the Ivy League, this time partnering with Yale University to move early stage research from the university's labs into late preclinical and IND-ready assets for third parties to license. The Yale collaboration is upstream of the biotech's 2011 deal with Harvard University because the projects are not predefined.